Senseonics Holdings Inc (SENS) Q4 2025 Earnings Call Transcript

Why It Matters

The turnaround demonstrates that a fully integrated CGM maker can accelerate growth, capture higher margins, and expand globally, reshaping competitive dynamics in diabetes care.

Key Takeaways

• Full-year revenue $35.3M, up 60% YoY.
• Gross margin exceeded 50% by year‑end.
• In‑house commercialization eliminates Ascensia revenue sharing.
• Eversense 365 integrated with Sequel Twist pump.
• 2026 revenue guidance $58‑62M, operating expenses $150‑160M.

Pulse Analysis

The continuous glucose monitoring (CGM) market is consolidating around longer‑lasting sensors, and Senseonics’ year‑long Eversense 365 positions it uniquely against weekly and monthly competitors. By internalizing sales, marketing, and service functions, the company not only removes the Ascensia revenue‑sharing layer but also gains granular insight into patient acquisition costs and retention metrics. This operational shift, coupled with a gross‑margin expansion to over 50%, signals a maturing business model that can sustain higher profitability as the sensor base scales.

A pivotal development is the integration of Eversense 365 with Sequel’s Twist automated insulin delivery system, creating a seamless iCGM‑pump ecosystem for type‑1 diabetics. The partnership eliminates the need for frequent sensor changes, enhancing patient adherence and opening cross‑sell opportunities. Simultaneously, CE‑mark approval unlocks entry into key European markets—Germany, Italy, Spain, and Sweden—where demand for year‑long CGM solutions remains untapped. The anticipated 20% contribution of European revenue in 2026 diversifies the company’s geographic exposure and reduces reliance on the U.S. reimbursement cycle.

Financially, Senseonics projects $58‑62 million in 2026 revenue, reflecting 65‑76% growth, but this comes with a steep rise in operating expenses to $150‑160 million, driven by expanded SG&A and a $5 million R&D boost for the Gemini pivotal trial. Cash utilization of $110‑120 million, offset by a $94.3 million cash balance and access to an additional $65 million non‑dilutive facility, will test liquidity management. Investors must weigh the upside of accelerated patient acquisition and margin improvement against the heightened cash burn and execution risk of the in‑house commercial model.